ABO and Alzheimer disease: Recently, an AβO monoclonal antibody produced by Biogen, aducanumab, reduced Aβ levels in the brain and slowed the clinical recognition decline of patients with AD [4], implying that the specificity of antibodies for Aβ oligomers is important for the development of AD therapeutics.